论文部分内容阅读
Cetuximab是抗表皮生长因子受体(EGFR)单克隆抗体之一,其可特异地与EGFR结合,通过阻断配体与EGFR结合而抑制肿瘤生长。大量临床前及临床试验均证实Cetuximab单药及联合化疗和/或放疗的抗肿瘤作用,同时在核医学、影像学及疫苗研究等方面也具有较广阔的应用前景。
Cetuximab is one of the monoclonal antibodies against epidermal growth factor receptor (EGFR) that specifically binds to EGFR and inhibits tumor growth by blocking ligand binding to EGFR. A large number of preclinical and clinical trials have confirmed the anti-tumor effects of Cetuximab alone and combined with chemotherapy and/or radiotherapy, and also have broad application prospects in nuclear medicine, imaging, and vaccine research.